Integra Lifesciences vs Teleflex
Teleflex reported revenue of $2.0 billion in fiscal 2025, 1.2 times Integra Lifesciences' $1.6 billion in fiscal 2025. Integra Lifesciences' revenue grew 1.5% in its latest year, and Teleflex's grew 17.2%. Integra Lifesciences had an operating margin of -30.2%, against 5.9% at Teleflex. Free cash flow was −$31 million at Integra Lifesciences and $1 million at Teleflex.
Side by side
| Integra Lifesciences | Teleflex | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.6B | $2.0B |
| Revenue growth | 1.5% | 17.2% |
| Revenue growth a year, last 5 years | 3.6% | −4.7% |
| Gross margin | 50.9% | 56.2% |
| Operating margin | −30.2% | 5.9% |
| Net margin | −31.6% | −45.5% |
| Free cash flow | −$31M | $1M |
| Free cash flow margin | −1.9% | 0.1% |
| Return on capital | −22.0% | 2.1% |
| Net debt to EBITDA | — | 7.6x |
| Dividends and buybacks | $0M | $360M |
| Change in diluted share count | −0.4% | −5.0% |
| Last close | $13.42 | $150.87 |
| P/E at the last close | 78.9× | 18.3× |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 5 of 9 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Integra LifesciencesTeleflex
Operating margin
Percent of revenue
Integra LifesciencesTeleflex
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Integra LifesciencesTeleflex
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Integra Lifesciences and Teleflex pages.